Almac Sciences has announced the expansion of its technology capabilities within its API services and chemical development portfolio through implementation of continuous flow expertise.
Member of the Almac Group, Almac Sciences, has announced the expansion of its technology capabilities within its API services and chemical development portfolio through implementation of continuous flow expertise at its headquarters in the United Kingdom.
In a Jan. 7, 2019 press release, the company revealed that in addition to implementing continuous flow expertise, it will also introduce flow capacity within Arran Chemical Company, which is based in Ireland. These expanded capabilities form part of Almac Sciences four-year strategy, which is aimed at the development of Flow Assisted Synthesis Technology (FAST).
FAST will be focused on four key areas: high-pressure hydrogenations; high energy chemistry; oxidation; and photo-redox light emitting diode mediated chemistries. In support of this strategy, Innovate UK has awarded Almac Sciences with a Knowledge Transfer Partnership for the development of novel routes to chiral amines using flow technology. Further to this, Arran Chemical Company, in a joint effort with Queen’s University, Belfast, has secured a Horizon 2020-funded program to support four PhD studentships from 2019 for four years in line with the FAST strategy.
Prof. Tom Moody, VP Technology Development & Commercialization, Almac & Arran Chemical Company commented, “The introduction of continuous flow technology further enhances Almac Sciences’ capabilities within API development and manufacture. Flow technology is highly flexible, robust, economic, and regarded as the most exciting and innovative growth technology for the preparation of APIs. We are delighted to now offer this within our portfolio and will strive to continue providing world-class solutions to advance human health globally.”
Source: Almac Group
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.